HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NSC 109268

inhibits both proteasome degradation and phosphatase 2Calpha; structure in first source

Also Known As:

NSC-109268; NSC109268

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Siede, Wolfram: 3 articles (01/2013 - 05/2010)
2.	Jain, Dilip: 2 articles (01/2013 - 10/2010)
3.	Basu, Alakananda: 2 articles (10/2010 - 05/2010)
4.	Patel, Nila: 1 article (10/2010)
5.	Roque, Rouel: 1 article (10/2010)
6.	Shelton, Melanie: 1 article (10/2010)
7.	Adkins, Brett: 1 article (05/2010)
8.	Basu, Chandreyi: 1 article (05/2010)
9.	Shankar, Eswar: 1 article (05/2010)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 05/10/2010 - "These results demonstrate that NSC109268 enhances sensitivity of ovarian cancer 2008 cells to cisplatin independent of p53." 05/10/2010 - "NSC109268 enhanced sensitivity of ovarian cancer 2008 cells and its cisplatin resistant counterpart 2008/C13* cells which express wild-type p53. " 10/01/2010 - "The enhancement of cisplatin sensitivity by NSC109268 found in yeast was confirmed in cisplatin-sensitive and cisplatin-resistant human ovarian cancer lines and in prostate cancer cells. "
2.	Neoplasms (Cancer) 01/01/2013 - "Previous investigation revealed an enhancement of CP sensitivity by NSC109268 in wild-type Saccharomyces cerevisiae and CP-sensitive and -resistant cancer cell lines that correlated with a slower S phase traversal. " 10/01/2010 - "Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression."
3.	Prostatic Neoplasms (Prostate Cancer) 10/01/2010 - "The enhancement of cisplatin sensitivity by NSC109268 found in yeast was confirmed in cisplatin-sensitive and cisplatin-resistant human ovarian cancer lines and in prostate cancer cells. "

Related Drugs and Biologics

1.	Cisplatin (Platino)